GlobeNewswire Inc.··Vaxcyte, Inc.Vaxcyte's 31-Valent Pneumococcal Vaccine Advances to Phase 3 on Strong Clinical Data
Vaxcyte publishes positive Phase 1/2 data for VAX-31, a 31-valent pneumococcal vaccine, and advances to Phase 3 trials with topline results expected Q4 2026.
PCVXPhase 3 clinical trialBreakthrough Therapy Designation